Lidocaine/tetracaine topical cream - Crescita Therapeutics
Alternative Names: Flexicaine; Pliaglis; S-Caine™ Peel; Tetracaine/lidocaine topical cream - Crescita TherapeuticsLatest Information Update: 10 Sep 2025
At a glance
- Originator ZARS
- Developer Crescita Therapeutics; Galderma; Nuvo Research
- Class Acetanilides; Aminobenzoic acids; Local anaesthetics; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Procedural pain
- Phase II Unspecified
- Discontinued Postherpetic neuralgia
Most Recent Events
- 23 May 2025 Lidocaine/tetracaine topical cream - Crescita Therapeutics is available for licensing in Germany, United Kingdom, Ireland, Switzerland, Brazil, Romania, Belgium, Netherlands, Luxembourg as of 23 May 2025.
- 23 May 2025 Croma Pharma terminates licensing and supply agreement with Crescita Therapeutics for Lidocaine/tetracaine topical cream in Germany, the United Kingdom, Ireland, Switzerland, Brazil, Romania, Belgium, the Netherlands and Luxembourg
- 08 May 2024 Juyou Biotechnology plans a clinical trial for Procedural pain (Prevention) in China (Topical)